Live price temporarily unavailable.
Price history
Tilray Brands (TLRY) is a Health Care company. Latest news and coverage below.
IPO: July 19, 2018 · $17.00 offering · NASDAQ · View IPO details →
Tilray Brands revenue & net income history (FY2016–FY2026)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2021May 2021 | FY2022May 2022 | FY2023May 2023 | FY2024May 2024 | FY2025May 2025 | FY2026May 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.6M | $20.5M | $513.1M | $628.4M | $627.1M | $788.9M | $821.3M | $915.5M |
| Growth (year over year) | — | +62.4% | — | +22.5% | −0.2% | +25.8% | +4.1% | +11.5% |
| Gross profit | $2.67M | $11.4M | $123.2M | $116.8M | $147.0M | $223.4M | $240.6M | $260.4M |
| Gross margin | 21.1% | 55.4% | 24.0% | 18.6% | 23.4% | 28.3% | 29.3% | 28.4% |
| Operating income | −$7.05M | −$7.50M | −$132.2M | −$610.4M | −$1.37B | −$174.7M | −$2.28B | −$63.0M |
| Operating margin | −55.7% | −36.5% | −25.8% | −97.1% | −218.4% | −22.1% | −277.9% | −6.9% |
| Net income | −$7.88M | −$7.81M | −$367.4M | −$476.8M | −$1.45B | −$245.0M | −$2.19B | −$121.4M |
| Net margin | −62.3% | −38.0% | −71.6% | −75.9% | −231.6% | −31.1% | −266.3% | −13.3% |
| EPS (diluted) | −$11.00 | −$10.00 | −$13.60 | −$9.90 | −$23.50 | −$3.30 | −$24.56 | −$1.09 |
| Balance sheet | ||||||||
| Cash and equivalents | $7.53M | $2.32M | $488.5M | $415.9M | $206.6M | $228.3M | $221.7M | $226.0M |
| Total assets | — | $53.9M | $6.03B | $5.45B | $4.31B | $4.22B | $2.07B | $2.33B |
| Total liabilities | — | $58.8M | $1.56B | $1.01B | $977.3M | $778.5M | $584.8M | $733.1M |
| Long-term debt | — | $9.43M | $167.5M | $117.9M | — | — | — | — |
| Shareholders' equity | $2.53M | −$4.85M | $4.46B | $4.40B | $3.32B | $3.44B | $1.51B | $1.61B |
| Cash flow | ||||||||
| Operating cash flow | −$3.32M | −$6.00M | −$44.7M | −$177.3M | $7.91M | −$30.9M | −$94.6M | −$69.1M |
| Capital expenditure | $488.0K | $10.9M | $38.9M | $34.1M | $20.8M | $29.2M | $32.9M | — |
| Free cash flow | −$3.81M | −$16.9M | −$83.6M | −$211.3M | −$12.9M | −$60.2M | −$127.5M | — |
RevenueNet income
| Q1 FY25Aug 2024 | Q2 FY25Nov 2024 | Q3 FY25Feb 2025 | Q4 FY25†May 2025 | Q1 FY26Aug 2025 | Q2 FY26Nov 2025 | Q3 FY26Feb 2026 | Q4 FY26†May 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $200.0M | $210.9M | $185.8M | $224.5M | $209.5M | $217.5M | $206.7M | $281.7M |
| Growth (year over year) | +13.1% | +8.9% | −1.4% | −2.3% | +4.7% | +3.1% | +11.3% | +25.5% |
| Gross profit | $59.7M | $61.2M | $52.0M | $67.6M | $57.5M | $57.5M | $55.0M | $90.5M |
| Gross margin | 29.8% | 29.0% | 28.0% | 30.1% | 27.4% | 26.4% | 26.6% | 32.1% |
| Operating income | −$36.6M | −$42.2M | −$759.9M | −$1.44B | $2.09M | −$22.3M | −$26.4M | −$16.5M |
| Operating margin | −18.3% | −20.0% | −409.0% | −643.1% | 1.0% | −10.2% | −12.8% | −5.8% |
| Net income | −$39.2M | −$85.3M | −$789.4M | −$1.27B | −$322.0K | −$44.9M | −$26.6M | −$49.6M |
| Net margin | −19.6% | −40.5% | −424.9% | −566.9% | −0.2% | −20.7% | −12.9% | −17.6% |
| EPS (diluted) | −$0.40 | −$0.99 | −$8.69 | −$14.48 | $0.00 | −$0.41 | −$0.24 | −$0.44 |
| Balance sheet | ||||||||
| Cash and equivalents | $205.2M | $189.7M | — | $221.7M | $264.8M | $246.7M | $204.6M | $226.0M |
| Total assets | $4.26B | $4.19B | — | $2.07B | $2.08B | $2.10B | $2.07B | $2.33B |
| Total liabilities | $778.5M | $738.1M | — | $584.8M | $562.0M | $552.1M | $549.1M | $733.1M |
| Shareholders' equity | $3.48B | $3.47B | $2.70B | $1.51B | $1.54B | $1.58B | $1.56B | $1.61B |
| Cash flow | ||||||||
| Operating cash flow | −$35.3M | −$40.7M | −$5.76M | −$12.8M | −$1.34M | −$8.54M | −$21.9M | −$37.3M |
| Capital expenditure | $6.74M | $5.44M | $14.4M | $6.33M | — | — | — | — |
| Free cash flow | −$42.0M | −$46.2M | −$20.2M | −$19.1M | — | — | — | — |
From Tilray Brands's 10-K and 10-Q filings with the SEC; its fiscal year ends in May. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Tilray Brands
Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand,Latin America, with growing facilities in Germany, Portugal and the United Kingdom.
- Headquarters
- New York, New York From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International